0000914475-24-000092.txt : 20240315
0000914475-24-000092.hdr.sgml : 20240315
20240315171938
ACCESSION NUMBER: 0000914475-24-000092
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240313
FILED AS OF DATE: 20240315
DATE AS OF CHANGE: 20240315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: POPS RICHARD F
CENTRAL INDEX KEY: 0001126490
ORGANIZATION NAME:
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 24756028
MAIL ADDRESS:
STREET 1: 10555 SCIENCE CENTER DR
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
wk-form4_1710537566.xml
FORM 4
X0508
4
2024-03-13
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001126490
POPS RICHARD F
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
1
0
0
0
1
Common Stock
2024-03-13
4
M
0
23200
42.76
A
52712
D
Common Stock
2024-03-13
4
S
0
23200
140.3285
D
29512
D
Non-Qualified Stock Option
42.76
2024-03-13
4
M
0
23200
42.76
D
2025-05-28
Common Stock
23200
0
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 21, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.77. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025.
/s/ Darin Lippoldt, Attorney-in-Fact
2024-03-15